We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+15.66%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.45B
AUM Growth
+$7.66M
Cap. Flow
-$5.91M
Cap. Flow %
-0.41%
Top 10 Hldgs %
77.82%
Holding
53
New
5
Increased
6
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$13.6M
2
VSTM icon
Verastem
VSTM
+$10.7M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$8.25M
4
DCTH icon
Delcath Systems
DCTH
+$7.39M
5
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$7.02M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$21.7M
2
LEGN icon
Legend Biotech
LEGN
+$11.8M
3
GERN icon
Geron
GERN
+$7.85M
4
BLU
BELLUS Health Inc.
BLU
+$7.32M
5
MRUS
Merus
MRUS
+$6.51M

Sector Composition

Rank Sector Weight
1 Healthcare 99.19%
2 Materials 0.55%
3 Consumer Staples 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
51
Vaxcyte
PCVX
$7.9B
– –
-579,508
Closed -$21.7M
UTRS
52
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
– –
-110,783
Closed -$486K
BLU
53
DELISTED
BELLUS Health Inc.
BLU
– –
-1,017,152
Closed -$7.32M
1 2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
LWIC
Leith Wheeler Investment Counsel Vancouver, British Columbia, Canada $1.21B AUM 12.04% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return

Vivo Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Vivo Capital held 53 positions worth $1.45B, up 0.53% from $1.44B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Vivo Capital's Q2 2023 filing shows 5 new, 6 increased, 4 reduced and 5 closed positions. Its largest new stake was Icosavax, Inc. Common Stock: 1,704,568 shares worth $16.9M. The largest sale was Vaxcyte, an estimated $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Materials and Consumer Staples.

  • Vivo Capital's largest Q2 2023 buy was Icosavax, Inc. Common Stock: 1,704,568 shares worth $16.9M.
  • Vivo Capital added most to Gracell Biotechnologies Inc. American Depositary Shares in Q2 2023, an estimated $7.02M increase.
  • Vivo Capital's biggest Q2 2023 reduction was Geron, cutting an estimated $7.85M.
  • Vivo Capital fully exited Vaxcyte in Q2 2023, selling an estimated $21.7M.
  • Vivo Capital's ten largest holdings make up 78% of its $1.45B portfolio in Q2 2023.
  • Vivo Capital opened 5 new positions and closed 5 in Q2 2023.
  • Vivo Capital's portfolio value rose 0.53% quarter-over-quarter to $1.45B.

Based on Vivo Capital's 13F filing for Q2 2023, filed 14 Aug 2023.